A venture capital arm of a global pharmaceutical in Asia, that also has an active in-licensing arm and specialty products incubator, has been established to invest in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds with an ultimate possibility of acquisition. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on CNS and respiratory diseases. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A publicly traded pharmaceutical company based in Western Europe is interested in licensing and M&A opportunities in its core therapeutic areas of urology, cardiovascular, gastrointestinal and metabolic diseases, and also in all rare disease/orphan drug assets. The firm will consider partnerships worldwide. Particularly in the rare disease space, the firm prefers to invest in global rights.

The firm is interested in early stage therapeutic partnerships in rare diseases, including in preclinical assets provided that there is strong preclinical proof of concept data for the asset (such as strong efficacy data from an animal model that are relevant and reflective of the human condition). The firm generally does not invest in rare oncology assets but is otherwise open to a wide range of rare disease opportunities. In other core areas (urology, cardiovascular, gastrointestinal, and central nervous system) the firm prefers to partner with companies that have obtained solid human proof of concept data. The firm can be a hands-on development and manufacturing partner in small molecule therapeutics, but not in biologics or cell therapies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M in equity with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in USA, Europe and China.  The firm’s China offices can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture firm with offices in Europe and Asia invests in life science companies in the Benelux region, Germany, France, and parts of Asia, all near where the firm has operations. The firm may invest up to EUR 10 million in early stage venture rounds as well as clinical stage opportunities.

The firm invests in the prevention and treatment of chronic diseases. In terms of sector, the firm makes investments in therapeutics, medtech and digital health and diagnostics. Generally the firm invests in assets that are close to IND or close to registration for first in human trials.

The firm is interested in opportunities with a driven entrepreneurial team, good IP protection, which are addressing important medical needs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm with offices in Western Europe makes biotech and medtech investments from an evergreen fund. The firm typically makes initial investments of EUR 3-10m at the Series A or B stage, and may commit EUR 25m over the life of an investment. The firm invests across Europe, and aims to make at least 4 life science investments per year (2-3 biotech and 1-2 medtech investments).

The firm invests across the biotech and medtech sectors. Within the biotech sector, the firm prefers to invest in platform technologies rather than in single asset companies, and will invest as early as the preclinical stage. The firm will consider any therapeutic area, and has an interest in orphan drugs; due to having a large existing portfolio in immuno-oncology, the firm is not emphasizing this field at present. The firm prefers opportunities that do not require very large clinical trials. For medical devices, the firm prefers to invest in companies with products with a global potential, that are close to acquiring a CE Mark and that are preparing commercialization. The firm is also interested in enabling technologies such as next-gen PCR and lab equipment.

The firm does not invest in company-creation opportunities: the firm prefers to work with companies that already have high-quality management teams that have proven themselves through past success in the life science industry, and who have a strong network within the industry. The firm also considers the company’s capital efficiency, future capital needs, and the strength of the company’s prior investment syndicate. The firm prefers to lead or co-lead investments, and is a highly activist investor at a portfolio company’s board level.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to PhI stages, and will generally invest $5-10M in series A rounds. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, the firm is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Corporate Finance firm focused on venture and private equity investments supports SMEs across Europe with attention to Austria. The company has built a track record of creating significant value as investors by developing deep industry expertise in sectors including renewable energy, high-tech and bio-tech.

The firm is interested in companies in the therapeutics and diagnostics space in particular and is open to considering medical device companies as well. The firm is open to any indication and sub-sector but requires that the firm’s asset be ready to enter a Phase I study in order to be considered.

The firm is looking for private companies with exceptional management teams in place. The firm often looks to take a board seat and provide a lot more than just financial aid to companies they invest in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.